Cullinan Therapeutics, Inc. (CGEM)
After hours:
| Previous close | 17.09 |
| Open | 17.42 |
| Bid | 12.46 x 200 |
| Ask | 17.45 x 100 |
| Day's range | 17.00 - 17.71 |
| 52-week range | 7.64 - 30.19 |
| Volume | |
| Avg. volume | 982,483 |
| Market cap | 1.005B |
| Beta (5Y monthly) | -0.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Institutional owners may ignore Cullinan Therapeutics, Inc.'s (NASDAQ:CGEM) recent US$92m market cap decline as longer-term profits stay in the green
Key Insights Given the large stake in the stock by institutions, Cullinan Therapeutics' stock price might be vulnerable...
- GuruFocus.com
Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ...
Jennifer Michaelson, Chief Scientific Officer at Cullinan Therapeutics Inc (NASDAQ:CGEM), sold 63,606 shares of the company on May 7, 2024.
- Benzinga
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
A recent academic case study, published on April 22, examined using Amgen Inc’s (NASDAQ:AMGN) Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with severe systemic sclerosis. The findings have implications for Cullinan Therapeutics Inc’s (NASDAQ:CGEM) CLN-978, a similar CD19xCD3 bispecific T-cell engager. Most recently, Cullinan Therapeutics, formerly Cullinan Oncology, announced its plans to expand into autoimmune diseases and intends to pursue the development of CLN-978 in au
